FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322156921> ?p ?o ?g. }

• W2322156921 endingPage "775" @default.
• W2322156921 startingPage "775.2" @default.
• W2322156921 abstract "<h3>Background</h3> Hypertension (HTN) is a prevalent comorbidity in gout and occurs due to various combinations of factors (hyperuricemia, pain, renal function, severity of HTN). During gout attack, the development of unstable HTN can occur, with NSAIDs playing an important role in its development. <h3>Objectives</h3> to determine factors contributing to destabilized HTN in patients with gout arthritis (GA) regularly taking their antihypertensive treatment (AHT). <h3>Methods</h3> 405 patients enrolled with acute GA fulfilled ACR 1977 classification criteria for acute GA (1977, ACR). 87,9% of patients were males with the mean age of 56,6±9,5 years and average disease duration of 8,4±6,8 years. All patients were given a short-life NSAIDs. Destabilized HTN was defined as sitting blood pressure (BP) >140/90mmHg, demanding correction of AHT. 74,1% (n=300) of patients had HTN and only 61,7% (n=185) of them regularly took their AHT. The latter were divided into 2 groups: group 1 (n=73) without elevated BP during the treatment period (group HTN-) and group 2 (n=112) with destabilized HTN (group HTN+). The groups were comparable in sex, age and duration of gout. Characteristics of gout, parameters of severity of HTN, doses of NSAIDs and duration of treatment, 60 parameters in total, were compared between the groups HTN+ and HTN-. We defined the factors of destabilized HTN in patients with acute GA and effective treatment of HTN. <h3>Results</h3> Comparing various features of the groups HTN+ and HTN- we found that the patients from group HTN+ had more frequent episodes of proteinuria including MAU (OR-2,67; 95%Cl, 1,72-2,69; p=0,027). In the same group, we observed statistically more patients with elevated levels of C-reactive protein (OR-2,12, 95%Cl, 1,68 – 2,66; p=0,016). Before the first registration of raised BP, the duration of acute GA treatment with NSAIDs was statistically different between the groups: the patients receiving NSAIDs for 20 days and more (AUC =0,63, p=0,016, S=90,4%, Sp-33,9%, OR-3,23, 95%Cl - 2,61-4,00) had higher risk of HTN destabilization. We found no differences between the groups in pain characteristics (VAS, number of affected and tender joints). <h3>Conclusions</h3> Destabilized HTN during gout flares treated with NSAIDs was observed in 60,5% of patients regularly receiving their AHT. Destabilized HTN in patients with GA despite regular and effective AHT before GA was associated with the presence of proteinuria and elevated level of C-reactive protein, as well as with the duration of NSAID treatment. In these cases, the AHT should be intensified during gout attacks treated with NSAIDs, more appropriate anti-inflammatory approach being required. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1464" @default.
• W2322156921 created "2016-06-24" @default.
• W2322156921 creator A5037082620 @default.
• W2322156921 creator A5087198083 @default.
• W2322156921 date "2014-06-01" @default.
• W2322156921 modified "2023-09-25" @default.
• W2322156921 title "SAT0505 Factors Associated with Destabilized Hypertension during the Treatment of Gouty Arthritis with Nsaids" @default.
• W2322156921 doi "https://doi.org/10.1136/annrheumdis-2014-eular.1464" @default.
• W2322156921 hasPublicationYear "2014" @default.
• W2322156921 type Work @default.
• W2322156921 sameAs 2322156921 @default.
• W2322156921 citedByCount "0" @default.
• W2322156921 crossrefType "journal-article" @default.
• W2322156921 hasAuthorship W2322156921A5037082620 @default.
• W2322156921 hasAuthorship W2322156921A5087198083 @default.
• W2322156921 hasConcept C126322002 @default.
• W2322156921 hasConcept C198451711 @default.
• W2322156921 hasConcept C2777077863 @default.
• W2322156921 hasConcept C2779134260 @default.
• W2322156921 hasConcept C2779159551 @default.
• W2322156921 hasConcept C2779721657 @default.
• W2322156921 hasConcept C2779881121 @default.
• W2322156921 hasConcept C2780402116 @default.
• W2322156921 hasConcept C71924100 @default.
• W2322156921 hasConcept C84393581 @default.
• W2322156921 hasConceptScore W2322156921C126322002 @default.
• W2322156921 hasConceptScore W2322156921C198451711 @default.
• W2322156921 hasConceptScore W2322156921C2777077863 @default.
• W2322156921 hasConceptScore W2322156921C2779134260 @default.
• W2322156921 hasConceptScore W2322156921C2779159551 @default.
• W2322156921 hasConceptScore W2322156921C2779721657 @default.
• W2322156921 hasConceptScore W2322156921C2779881121 @default.
• W2322156921 hasConceptScore W2322156921C2780402116 @default.
• W2322156921 hasConceptScore W2322156921C71924100 @default.
• W2322156921 hasConceptScore W2322156921C84393581 @default.
• W2322156921 hasIssue "Suppl 2" @default.
• W2322156921 hasLocation W23221569211 @default.
• W2322156921 hasOpenAccess W2322156921 @default.
• W2322156921 hasPrimaryLocation W23221569211 @default.
• W2322156921 hasRelatedWork W2013485359 @default.
• W2322156921 hasRelatedWork W2402844998 @default.
• W2322156921 hasRelatedWork W2526559013 @default.
• W2322156921 hasRelatedWork W2591899693 @default.
• W2322156921 hasRelatedWork W2771750966 @default.
• W2322156921 hasRelatedWork W2790396910 @default.
• W2322156921 hasRelatedWork W2955070532 @default.
• W2322156921 hasRelatedWork W3018822530 @default.
• W2322156921 hasRelatedWork W3027462351 @default.
• W2322156921 hasRelatedWork W4362520755 @default.
• W2322156921 hasVolume "73" @default.
• W2322156921 isParatext "false" @default.
• W2322156921 isRetracted "false" @default.
• W2322156921 magId "2322156921" @default.
• W2322156921 workType "article" @default.